Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

370 17 Immunotoxins and Recombinant Immunotoxins in Cancer Therapy
antigen present on mesothelium, mesotheliomas,
and ovarian cancers. Proc
Natl Acad Sci USA 93: 136±40.
14 Pastan I, Lovelace E, Rutherford AV,
Kunwar S,Willingham MC, Peehl DM
(1993) PR1 ± a monoclonal antibody that
reacts with an antigen on the surface of
normal and malignant prostate cells.
J Natl Cancer Inst 85: 1149±54.
15 Pastan I, Lovelace ET, Gallo MG,
Rutherford AV, Magnani JL, Willingham
MC (1991) Characterization
of monoclonal antibodies B1 and B3
that react with mucinous adenocarcinomas.
Cancer Res 51: 3781±7.
16 Wang RF, Rosenberg SA (1999)
Human tumor antigens for cancer vaccine
development. Immunol Rev 170:
85±100.
17 Rosenberg SA (1999) A new era for
cancer immunotherapy based on the
genes that encode cancer antigens. Immunity
10: 281±7.
18 Chaudhary VK, FitzGerald DJ, Adhya
S, Pastan I (1987) Activity of a recombinant
fusion protein between
transforming growth factor type a and
Pseudomonas toxin. Proc Natl Acad Sci
USA 84: 4538±42.
19 Prior TI, Helman LJ, FitzGerald DJ,
Pastan I (1991) Cytotoxic activity of a
recombinant fusion protein between insulin-like
growth factor I and Pseudomonas
exotoxin. Cancer Res 51: 174±80.
20 Siegall CB, Epstein S, Speir E, et al.
(1991) Cytotoxic activity of chimeric
proteins composed of acidic fibroblast
growth factor and Pseudomonas exotoxin
on a variety of cell types. FASEBJ
13: 2843±9.
21 Lorberboum-Galski H, FitzGerald
D, Chaudhary V, Adhya S, Pastan I
(1988) Cytotoxic activity of an interleukin
2±Pseudomonas exotoxin chimeric
protein produced in Escherichia coli.
Proc Natl Acad Sci USA 85: 1922±6.
22 Debinski W, Puri RK, Kreitman RJ,
Pastan I (1993) A wide range of human
cancers express interleukin 4 (IL-4) receptors
that can be targeted with chimeric
toxin composed of IL-4 and Pseudomonas
exotoxin. J Biol Chem 268:
14065±70.
23 Siegall CB, Schwab G, Nordan RP,
FitzGerald DJ, Pastan I (1990) Expression
of the interleukin 6 receptor
and interleukin 6 in prostate carcinoma
cells. Cancer Res 50: 7786±8.
24 Komatsu N, Oda T, Muramatsu T
(1998) Involvement of both caspase-like
proteases and serine proteases in apoptotic
cell death induced by ricin, modeccin,
diphtheria toxin, and Pseudomonas
toxin. J Biol Chem 124: 1038±44.
25 Bolognesi A, Tazzari PL, Olivieri F,
et al. (1996) Induction of apoptosis by
ribosome-inactivating proteins and related
immunotoxins. Int J Cancer 68:
349±55.
26 Vitetta ES, Fulton RJ, May RD,
Till M, Uhr JW (1987) Redesigning
nature's poisons to create anti-tumor reagents.
Science 238: 1098±104.
27 Pastan I, FitzGerald D (1991) Recombinant
toxins for cancer treatment.
Science 254: 1173±7.
28 Moskaug JO, Sletten K, Sandvig K,
Olsnes S (1989) Translocation of
diphtheria toxin A-fragment to the cytosol.
Role of the site of interfragment
cleavage. J Biol Chem 264: 15709±13.
29 Ogata M, Chaudhary VK, Pastan I,
FitzGerald DJ (1990) Processing of
Pseudomonas exotoxin by a cellular protease
results in the generation of a
37,000-Da toxin fragment that is translocated
to the cytosol. J Biol Chem 265:
20678±85.
30 Brinkmann U, Pastan I (1995) Recombinant
immunotoxins: from basic
research to cancer therapy. Methods:
Methods Enzymol. 8: 143±56.
31 Olsnes S, Pihl A. (1982) Toxic lectins
and related proteins. In: Cohen P, van
Heyningen S, eds. Molecular Action of
Toxins and Viruses. New York: Elsevier
Science, p. 51.
32 Eiklid K, Olsnes S, Pihl A (1980) Entry
of lethal doses of abrin, ricin and
modeccin into the cytosol of HeLa cells.
Exp Cell Res 126: 321±9.
33 Endo Y, Tsurigi K (1987) RNA N-glycosidase
activity of ricin A-chain. Mechanism
of action of the toxic lectin ricin on
eukaryotic ribosomes. J BioI Chem 262:
8128±30.
34 Shen G-L, Li J-L, Ghetie MA,
Ghetie V, et al. (1988) Evaluation of